Skip to main content

Table 3 PRA mRNA expression before and after treatment as a function of PRA status on day 1

From: Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma

  

Median ± SD of PRA expression (2^∆-Ct)

PRA status at day 1

Day 1

Day 15

Control group

PRA+

0.05 ± 0.02

0.08 ± 0.06

PRA-

0.01 ± 0.01

0.03 ± 0.00

Treated group

PRA+

0.08 ± 0.05

0.04 ± 0.02*

PRA-

0.01 ± 0.01

0.02 ± 0.04

  1. PRA: Progesterone receptor isoform A; SD: Standard deviation; PRA+: Progesterone receptor isoform A positive; PRA-: Progesterone receptor isoform A negative. *P < 0.05.